HER2/neu POSTIVE BREAST CANCER - IMPROVED OVERALL SURVIVAL WITH PERTUZUMAB

PERJETA® (pertuzumab) is a HER2/neu receptor antagonist indicated in combination with Herceptin® (trastuzumab) and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti‑HER2 therapy or chemotherapy for metastatic disease